← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2007Last known activity
Aug 22, 2022
Timeline
2000s
- Jun 1, 2007
AIO-Studien-gGmbH— Founded
Drugs by trial phase (55 distinct, 55 trials)
Phase 4 (2 own, 0 via acquisition)
Phase 3 (11 own, 0 via acquisition)
Phase 2 (41 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma of Lung
- Ascites
- Bile Duct Neoplasms
- Biliary Tract Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Hepatocellular
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Cholangiocarcinoma
- Colorectal Neoplasms
- Disease Progression
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Gallbladder Neoplasms
- Gastrointestinal Neoplasms
- Head and Neck Neoplasms
- Liver Neoplasms
- Lung Neoplasms
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Second Primary
- Neoplasms, Squamous Cell
- Neuroendocrine Tumors
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Rectal Neoplasms
- Sarcoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Thromboembolism
- Urinary Bladder Neoplasms
- Venous Thromboembolism
Recent trials (50)
- NCT05510895Lead sponsorPhase 2Aug 22, 2022
- NCT05383001Lead sponsorPhase 2May 20, 2022
- NCT05212012Lead sponsorPhase 1/Phase 2Feb 17, 2022
- NCT05089916Lead sponsorPhase 2Dec 31, 2021
- NCT05118724Lead sponsorPhase 2Nov 15, 2021
- NCT07280377CollaboratorPhase 1/Phase 2Oct 27, 2021
- NCT04727541Lead sponsorPhase 2Jul 8, 2021
- NCT04221529Lead sponsorPhase 2Jan 6, 2020
- NCT03620123Lead sponsorPhase 2Jul 16, 2018
- NCT03572582Lead sponsorPhase 2Jun 14, 2018
- NCT04046614Lead sponsorPhase 1/Phase 2May 25, 2018
- NCT03473574Lead sponsorPhase 2May 2, 2018
- NCT03468335Lead sponsorPhase 3Mar 31, 2018
- NCT03409848Lead sponsorPhase 2Mar 1, 2018
- NCT03416244Lead sponsorPhase 2Feb 21, 2018
Details
- Founded
- Berlin, DE Jun 1, 2007
- Last known activity
- Aug 22, 2022
Notes
CRO